These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31911080)

  • 1. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
    Hu G; Tu W; Yang L; Peng G; Yang L
    Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.
    Wang L; Qu J; Zhou N; Hou H; Jiang M; Zhang X
    Biomed Pharmacother; 2020 Oct; 130():110626. PubMed ID: 32791396
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Li L; Li M; Jiang Z; Wang X
    Cells; 2019 Jul; 8(7):. PubMed ID: 31277418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas.
    Aslan K; Turco V; Blobner J; Sonner JK; Liuzzi AR; Núñez NG; De Feo D; Kickingereder P; Fischer M; Green E; Sadik A; Friedrich M; Sanghvi K; Kilian M; Cichon F; Wolf L; Jähne K; von Landenberg A; Bunse L; Sahm F; Schrimpf D; Meyer J; Alexander A; Brugnara G; Röth R; Pfleiderer K; Niesler B; von Deimling A; Opitz C; Breckwoldt MO; Heiland S; Bendszus M; Wick W; Becher B; Platten M
    Nat Commun; 2020 Feb; 11(1):931. PubMed ID: 32071302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
    Shen J; Ju Z; Zhao W; Wang L; Peng Y; Ge Z; Nagel ZD; Zou J; Wang C; Kapoor P; Ma X; Ma D; Liang J; Song S; Liu J; Samson LD; Ajani JA; Li GM; Liang H; Shen X; Mills GB; Peng G
    Nat Med; 2018 May; 24(5):556-562. PubMed ID: 29736026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
    Lee EK; Konstantinopoulos PA
    Trends Cancer; 2019 Sep; 5(9):524-528. PubMed ID: 31474356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
    Yang L; Yang G; Ding Y; Huang Y; Liu S; Zhou L; Wei W; Wang J; Hu G
    Oncol Rep; 2018 Jul; 40(1):479-487. PubMed ID: 29767248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
    You W; Shang B; Sun J; Liu X; Su L; Jiang S
    Oncol Rep; 2020 Aug; 44(2):424-437. PubMed ID: 32627031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 18. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
    Morrissey SM; Yan J
    Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.